GlaxoSmithKline Gets Approval for Myeloma Treatment in EU
August 27 2020 - 2:50AM
Dow Jones News
By Matteo Castia
GlaxoSmithKline PLC said late Wednesday that the European
Commission has given conditional marketing authorization to its
anti-B-cell maturation antigen therapy belantamab mafodotin.
The British pharmaceuticals giant said belantamab mafodotin has
been approved as a monotherapy for the treatment of multiple
myeloma in adult patient, in whom the disease was unresponsive to
previous treatment.
Earlier this month, the U.S. Food and Drug Administration
approved the use of belantamab mafodotin as a monotherapy in the
U.S. too.
Write to Matteo Castia at matteo.castia@dowjones.com
(END) Dow Jones Newswires
August 27, 2020 02:35 ET (06:35 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024
